Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
Published preclinical data in widely used MPTP non-human primate model of Parkinson's disease show AV-101 reduced levodopa-induced dyskinesias without adverse side effects often observed with amantadine therapy, while also maintaining antiparkinsonian activity of levodopa
Mild dyskinesia, severe dyskinesia and Freezing of Gait (FOG) 
Looking for people who have phased out Carbidopa/Levodopa in favor of an all-mucuna program
citicoline as an adjunct therapy in PD
Citicoline as Adjuvant Therapy in Parkinson's Disease: A Systematic Review 2017
What kind of \"unusual body movements\" does stopping Levodopa cause?
